Key points are not available for this paper at this time.
The excellent results of R-CHOP followed by rituximab maintenance until progression for older patients with MCL persisted in a mature follow-up. Prolongation of rituximab maintenance beyond 2 years is effective and safe.
Kluin‐Nelemans et al. (Thu,) studied this question.